Although no FLT3 inhibitors have as yet been approved for clinical use, several are currently under clinical trials for the treatment of relapsed or refractory FLT3-ITD positive and negative AML patients as well as for maintenance therapy 9-11. This evidence concerns the gene FLT3 and acute myeloid leukemia.